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Abstract
High-dimensional gene expression data provide a rich source of information because they capture the expression
level of genes in dynamic states that reﬂect the biological functioning of a cell. For this reason, such data are suitable
to reveal systems related properties inside a cell, e.g., in order to elucidate molecular mechanisms of complex diseases
like breast or prostate cancer. However, this is not only strongly dependent on the sample size and the correlation
structure of a data set, but also on the statistical hypotheses tested. Many diﬀerent approaches have been developed
over the years to analyze gene expression data to (I) identify changes in single genes, (II) identify changes in gene sets
or pathways, and (III) identify changes in the correlation structure in pathways. In this paper, we review statistical
methods for all three types of approaches, including subtypes, in the context of cancer data and provide links to
software implementations and tools and address also the general problem of multiple hypotheses testing. Further, we
provide recommendations for the selection of such analysis methods.
Reviewers: This article was reviewed by Arcady Mushegian, Byung-Soo Kim and Joel Bader.
Keywords: Gene expression data, Cancer data, Statistical analysis methods, Pathway methods, Correlation structure,
Cancer genomics
Review
Background
The early driving forces in biology were reductionist
approaches. In general, a reductionist approach tries to
break-down a complex system into its parts list and
explains its properties as the sum of its individual com-
ponents. Hence, the individual constituents of a system
inform its higher level functions [1-4]. However, the ‘one
gene, one protein, one function’ working hypothesis [5]
is not suﬃcient in order to explain the many emergent
properties such as the phenotypic variability of organ-
isms or the heterogeneity of cancer [6]. For this reason,
nowadays, it is generally acknowledged that for achiev-
ing a functional understanding of biological systems, the
genes in a cell need to be studied as a functioning collec-
tive [2,3,7]. In such a system, the collective functioning of
groups of genes results in, for instance, signaling pathways
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or protein complexes that regulate cell diﬀerentiation,
transcription regulation or growth.
A systems integration at the cellular level has the poten-
tial to answer many, until now, unsolved questions about
biological systems and their collective functioning, reg-
ulatory programs for growth, development, phenotypic
variability and the causality of many complex diseases
[8-10]. Due to the enormous complexity of a cellular sys-
tem, where many processes and interactions at diﬀerent
levels inside a cell work in harmony to assure the vital
functioning of a cell, we need to understand key proper-
ties of biological systems like its robustness or modularity
[2,8] in order to enhance our understanding of complex
diseases. These complex interactions occurring within
a cell can be described by networks [11-13], including
gene regulatory networks [14,15], protein-protein inter-
action (PPI) networks [16,17], metabolic networks [18]
and transcription regulatory networks [19,20]. The net-
works are organized at diﬀerent cellular levels and enable
the functionality of the cell. The question now arising is
© 2012 Emmert-Streib et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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how can the complexity inside a cell be understood, and
analyzed?
The development of information processing technolo-
gies in the post genomic era enabled the generation of
huge amounts of data. In this review, we focus on gene
expression data from microarray platforms and summa-
rize three major types of analysis strategies: (I) Identi-
ﬁcation of changes in single genes, (II) identiﬁcation of
changes in gene sets or pathways, and (III) identiﬁcation of
changes in the correlation structure within pathways. We
discuss these methods in the context of cancer data sets
to emphasize their biological meaning, implications and
expressiveness.
Large-scale gene expression data
In the next section, we brieﬂy review high-throughput
technologies that enable the generation of large-scale gene
expression data [21-23].
Gene expression data frommicroarray
A microarray experiment measures genome-wide gene
expression levels of mRNA in a cell or a tissue sample
under a particular condition. A microarray chip quantiﬁes
the hybridization of ﬂuorecsent labeled target nucleotide
sequences to deﬁned complementary probe sequences
that are spotted on a glass or silicon slide. For diﬀer-
ent microarray platforms the spotted probes are synthetic
oligonucleotides ranging from 25 to 80 nucleotides or long
cDNA transcripts. Diﬀerent microarray platforms were
designed for a single-channel or a multi-channel experi-
mental setting. For single-channel arrays each condition
sample is hybridized separately on individual arrays using
a single dye. For multi-channel arrays multiple conditions
are hybridized together on individual arrays using mul-
tiple dyes. For example Aﬀymetrix is a single-channel
platform, where multiple oligonucleotide probes (probe-
set) of 25 bases are used to measure the concentration of a
mRNA transcript. The target mRNAs of expressed genes
are extracted from a treatment or a control sample, reverse
transcribed to cDNAs, labeled with a ﬂuorescent dye and
then hybridized to a microarray. An image of the microar-
ray captures laser induced emitted ﬂuoresent intensities of
the probes at each spot. The intensities give a proportional
measure of the corresponding mRNA concentration for
each gene that was deﬁned on the microarray.
Gene expression data from next generation sequencing
(RNA-seq)
The transcriptome of a cell comprises mRNA, tRNA,
rRNA, and short regulatory RNAs. RNA-seq is a tran-
scriptome sequencing approach that uses deep sequenc-
ing techniques such as 454 (Roche), genome analyzer
(Illumina solexa), SOLiD (support oligonucleotide lig-
ation detection), Polonator G.007, HeliScope (Helicos
BioSciences) and SMRT (single molecule real time
sequencing) [24].
RNA-seq has a wide variety of applications such as the
measurement of gene expression levels from transcribed
mRNA sequences [25]. In the ﬁrst step of the procedure
RNA is extracted from a given condition sample, frag-
mented, reverse transcribed to cDNA that is ligated to
adapters. In the second step a library of reads is generated
from the ligated fragments that are sequenced. In the third
step the reads are mapped to known exon sequences of
genes. The expression level of a gene is measured from the
normalized number of mapped sequences that mapped to
the known set of exon sequences of a gene. The RNA-seq
transcriptome sequencing approach overcomes several
limitations of microarrays for measuring gene expression.
For example, RNA-seq measures large ranges of expres-
sion levels from very low to highly expressed genes and
is able to consider unknown transcribed sequences. Since
the novelty of the methodology, gold standard proce-
dures for the management and processing of the data are
currently being established.
Gene expression data and cancer
Cancer is a multifactorial disease, i.e., the detection of
one mutation in one gene cannot explain the phenotypic
plurality of carcino- and pathogenesis by a one-to-one
relationship between genotype and phenotype. Instead,
cancer can be induced by a multitude of genetic and envi-
ronmental factors and the accumulation of such events.
The intervening of such complex factors makes in gen-
eral the characterization of complex diseases diﬃcult. For
this reason it is astonishing that the seminal work by
Weinberg et al. [6,26] presented a relative simple, system-
atic functional framework for cancer and the role diﬀerent
biological key processes are playing. In this paper, the so
called hallmarks of cancer have been deﬁned. According
to [6], the hallmarks of cancer (see Figure 1) are:
• self suﬃciency in growth signals
• insensitivity to anti-growth signals
• evading apoptosis
• limitless replicative potential
• sustained angiogenesis
• tissue invasion and metastasis
Later, this list has been extended by adding two further
hallmarks [26]
• deregulating cellular energetics
• avoiding immune destruction
and also two enabling characteristics
• genome instability
• mutation and tumor-promoting inﬂammation
Emmert-Streib et al. Biology Direct 2012, 7:44 Page 3 of 25
http://www.biology-direct.com/content/7/1/44
Avoiding immune
destruction
Limitless replicative
potential
Hallmark
s of Cancer
Hallmarksof Cancer
Insensitivity to
anti-growth signals
Self-sufficiency in
 growth signals
Deregulating cellular
energetics
Evading apoptosis
Tissue invasion
and metastasis
Sustained angiogenesis
Metabolic 
network
Protein 
network
Gene regulatory network
Signaling
network
Tumor promoting
inflammation
Genome instability
and mutation
enabling characteristics
extended hallmarks
Figure 1 The hallmarks of cancer and enabling characteristics [6,26].
It has been recognized that these hallmarks are gradu-
ally acquired by diﬀerent types of cancers, potentially, in
a variable order. This variability in the acquiring of these
disease-bearing processes is one of the indicators of the
complexity of cancer.
The biological processes in a cell are controlled and reg-
ulated by signaling pathways that are activated by internal
and external signaling receptors and factors. The sig-
naling pathways governing growth and cell proliferation
are likely dysregulated in their functioning in cancer. For
example, they become insensitive to anti-growth signals,
or they are dys-regulated in growth signaling pathways
by gaining autonomy in their growth. It is assumed that
interaction changes at various levels (genetic, mRNA or
protein) lead to the unlimited growth of cells instead of the
up-regulation or down-regulation of a single gene. Fur-
ther, sometimes, even a moderate change in the expres-
sion of a group of genes can lead to a signiﬁcant change in
the biological function of an organism [27].
Currently, the underlying processes that contribute to
cancer are being intensively investigated. However, so far,
the molecular causes that initiate and maintain cancer
are not well understood. For this reason, the understand-
ing of gene expression proﬁles, which provide signatures
of all the active genes and their interconnections in a
cell, contain valuable information about the functioning
of key pathways, as expressed by the hallmarks of cancer
and, hence, enable a practical investigation of functional
mechanisms thereof [28-36]. Despite the diﬀerent focus of
many studies of diﬀerent cancer types, common themes
in the form of ‘key pathways’ can be found throughout.
For instance, the NF-κB pathway involved in the cellu-
lar responses to external stimuli like cytokines or free
radicals, and immune response to infection [29,37-39];
the MAPK signaling pathway responsible for regulating
growth factor signaling including the RAF, MEK, and
MAPK cascade [34,39,40]; the p53 signaling pathways
involved in DNA damage control, apoptosis and inhi-
bition of angiogenesis [37,41,42]; or the Wnt signaling
pathway involved in cell diﬀerentiation, and cell polarity
[31,34,36,38].
Formulating biological hypotheses
A main goal of high-throughput gene expression anal-
ysis is to identify diﬀerentially expressed genes or gene
sets between two or more conditions to enable a func-
tional interpretation of the underlying condition-speciﬁc
mechanisms. The biological processes at the gene level are
complex in nature as they dynamically interact with each
other. A single gene can participate in diﬀerent biologi-
cal processes and regulate diﬀerent genes at diﬀerent time
points. The identiﬁcation of key genes or pathways is a
diﬃcult task, because their interactions are unknown. We
only observe the phenotypic outcome of test conditions
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and the corresponding gene expression patternsmeasured
from a tissue or cell culture. Univariate and multivariate
statistical methods can be applied in order to understand
such diﬀerences from a statistical perspective. The ﬁrst
type of approach that has been used to identify changes
in the gene expression is a diﬀerential gene expression
analysis. This approach is commonly used to compare
diﬀerent conditions of microarray samples to identify dif-
ferences between them. As a result, a single gene analysis
approach gives a list of genes that show a statistically
signiﬁcant diﬀerence between two conditions. For can-
cer, such genes may correspond to oncogenes or tumor
suppressor genes.
If we consider the underlying network where diﬀer-
ent biological functions are being described by groups of
interacting genes, a single gene analysis does not resolve
the biological functions that are aﬀected primarily in dis-
ease conditions and are causal factors of the disease. In
order to get a systematic understanding of the disease
or phenotypes we have to ﬁrst understand what biolog-
ical functions contribute to these changes, and perform
a comparison between conditions using groups of genes
deﬁned by biological pathways. This approach leads to
comparing gene expression data at the pathway level
where sets of genes are tested for diﬀerential expression.
Another interesting property that can be extracted
from gene expression data is the correlation structure of
gene expression proﬁles between all genes. This correla-
tion structure shows associations between genes which
directly or indirectly interact with each other [8,43-45].
Comparative analyses of gene pathways that consider the
correlation structure of expression data can provide a suit-
able test for the hypothesis of changes in the underlying
network.
In summary a gene expression data set can be used to
(I) identify diﬀerentially altered single genes, (II) identify
diﬀerentially expressed gene sets or pathways, and (III)
identify diﬀerentially correlated pathways. In the follow-
ing sections, we review statistical methods that have been
introduced to study the three problems (I-III) above. In
Figure 2 we give a graphical overview of the suchmethods.
Before we procede, we would like to point out that all
of these methods test statistical hypotheses [46]. That
implies that in order to understand a particular method
biologically, i.e., one is capable of providing a biological
interpretation, one needs to understand the underlying
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Figure 2 Classiﬁcation of diﬀerent univariate andmultivariate hypothesis testing basedmethods for gene expression data analysis. The
data are used to test diﬀerential expression and co-expression between two conditions for single gene and gene set based approaches.
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null hypothesis. In our opinion, it is helpful to approx-
imately categorize all statistical hypotheses into three
categories with respect to their biological interpretability,
whereas each category represents a diﬀerent degree of dif-
ﬁculty to ﬁnd a biological interpretation for a hypothesis.
In the following, we provide a brief discussion of these
three categories because it enables a better, potentially,
more plausible understanding of the methods presented
in the next sections.
In category one belong all hypotheses for which it is
relatively easy to ﬁnd a meaningful biological interpreta-
tion. An example from this category are tests that compare
mean values (μ), e.g., to identify the diﬀerential expres-
sion of genes (section ‘Diﬀerential expression of a gene’).
That means these tests use the mean as a test statistic.
Due to the fact that the underlying (probability) distribu-
tion of the genes represents, biologically, the activity of the
gene expressions, the interpretation of a null hypothesis
is directly derived thereof. For this reason the biological
interpretation of the rejection of the null hypothesis given
in Eqn. 2, is intuitively clear and appealing, because it
implies a change in the (mean) expression of genes which
may indicate a change in a biological function because the
number of available proteins may be altered.
In category two fall tests for which there are sev-
eral alternative biological interpretations. This makes the
interpretation of such tests ambivalent from a biological
perspective. As example for such a test, we consider the
detection of the diﬀerential variance of a gene (section
‘Diﬀerential variance of a gene’). Despite the fact that the
underlying probability distribution of the expression of
genes has a clear biological interpretation, the biologi-
cal interpretation for the rejection of the null hypothesis
in Eqn. 4 is not unique. For instance, a gene could have
a diﬀerent variance in two conditions because, e.g., in
condition one it is periodically expressed, whereas in con-
dition two it is constantly expressed on an intermediate
level. The former conditionmay be related to the cell cycle
or the circadian rhythm, or periodically triggered by an
external signaling factor that is released by the adminis-
tration of a medication that is regularly taken. A second
equally plausible interpretation could be that in one con-
dition the cell utilizes parallel pathways to transfer a signal
whereas in the other condition only one signaling chain is
used. The reason for the utilization of parallel pathways
could be triggered by stress factors, e.g., in the presence of
an infection, so that the cell is ‘running’ full power in order
to execute all necessary programs that have been initiated
by the presence of the intruder.
Lastly, for tests in category three it is very diﬃcult to
ﬁnd suﬃciently precise biological interpretations because,
statistically, these methods test ‘complex’ expressions. An
example for a test from this category is the N-statistic
(section ‘N-statistic’). The null hypothesis is based on
the comparison of two distributions rather than scalar
test statistics. In order to clarify the crucial diﬀerence
between the comparison of two distributions and scalar
test statistics we note that, theoretically, every probabil-
ity distribution can be written as a series expansion in its
moments [47]. This means a test for a distribution, com-
pares implicitly the moments of this distribution. Here the
(k-th) moment is deﬁned as the expectation value of a
random variable (to power k), i.e.,
mk = E[ xk] . (1)
An example for a moment is the mean (which is the ﬁrst
moment), other examples of entities that can be expressed
as a function of moments are the variance and the kurto-
sis. This means whenever the null hypothesis in Eqn. 39 is
rejected it could be because of a diﬀerence in anymoment
of which there are, theoretically, inﬁnite many. Put dif-
ferently, this kind of unspeciﬁcity makes this test very
powerful in the sense that it may detect any possible diﬀer-
ence two distributions can exhibit. On the other hand, if
the null hypothesis is rejected it is very diﬃcult to identify
a precise reason for its rejection. For instance, this could
be related to a diﬀerence in the mean, variance, kurtosis
or any higher moment or function thereof. These com-
binatorial factors do usually not allow to ﬁnd a concise
biological interpretation. Nevertheless, such a test can be
of valuable use, e.g., for diagnostic purposes.
Single-gene analysis
Single-gene based methods can be subdivided into three
major classes. A) Methods for detecting diﬀerential gene
expression, B) methods for detecting diﬀerential correla-
tion, and C) methods for detecting a diﬀerential variance.
Diﬀerential expression of a gene
The analysis of diﬀerential gene expression is based on the
mean expression change of individual genes. Suppose for a
gene gi in a microarray data set the mean expression value
for two conditions are μ1 and μ2 respectively. Then the
null hypothesis for the diﬀerential expression of the gene
gi is deﬁned as
H0 : μ1 = μ2 (2)
H1 : μ1 = μ2 (3)
A gene is called diﬀerentially expressed when H0 is
rejected. Figure 3A shows an example where the samples
for two conditions are drawn from two normal distribu-
tions with diﬀerent mean values, i.e., N(μ1 = 0, σ1 = 1)
and N(μ2 = 1, σ2 = 1).
The ﬁrst published studies for gene expression analysis
selected diﬀerentially expressed genes based on a fold-
change criteria between a treatment and control condition
[48]. For example, an early application of this measure was
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used to compare normal colon epithelium and primary
colon cancers [49]. Since then, many statistical approaches
have been developed to provide more robust measures.
Among the most popular methods are, e.g., SAM [50,51],
limma [52], and the empirical Bayes approach from Efron
et al. [53].
Diﬀerential variance of a gene
The analysis of diﬀerential variability (DV) aims to detect
a change in the variance of the gene expression values [54].
Suppose in a microarray expression data set, the mean
expression value of a gene i is μc and its variance σ 2c ,
for condition c = {1, 2}. Then, the null and alternative
hypothesis tested are:
H0 : σ 21 = σ 22 (4)
H1 : σ 21 = σ 22 (5)
A gene is called diﬀerentially variable when the null
hypothesis H0 is rejected. The DV analysis in [54] tests
H0 by using a F-test. In Figure 3B we show an example
for a gene with a constant mean, but a changed variance
in the two conditions. The samples for the two conditions
are drawn from a standard normal distribution with the
same mean but diﬀerent variances for the conditions, i.e.,
N(μ1 = 0, σ1 = 1), and N(μ2 = 0, σ2 = 2).
Diﬀerential correlation of a gene
The analysis of diﬀerential correlation aims to detect
changes in the dependency structure of a single gene [55].
Suppose ri = ri1, ..., rip denotes a p − 1 dimensional cor-
relation vector, whereas each component corresponds to
the correlation between gene i and one of the other p − 1
genes in a data set. Then for ri one obtains distribution
functions, denoted by FAri and F
B
ri , for condition A and B
and the following hypotheses:
H0 : FAri = FBri (6)
H1 : FAri = FBri (7)
A gene i is called diﬀerentially correlated when H0 is
rejected.
Gene-pair analysis
The functional activities of genes, as measured by gene
expression values, reﬂect the interplay of the genes and
their products in the underlying gene network. The objec-
tive of a gene-pair analysis is to identify either diﬀerential
co-correlated or diﬀerential co-expressed pairs of genes,
instead of individual genes. The reason for looking for
pairs of genes is that the concerted changes in genes is due
to their common membership in biological pathways.
The principle idea to detect correlation changes in gene-
pairs is visualized in Figure 3D. The data are sampled
from a multivariate normal distribution with a constant
mean vector for both conditions, μ1 = μ2 = (0, 1), but
a diﬀerent correlation of ρ1 = 0.8 and ρ1 = −0.2. The
point is despite no diﬀerence in the mean expression of
the gene-pair, there is a diﬀerence in their correlation.
In [56] a method (CorScor) has been proposed to iden-
tify such gene-pairs. In Figure 4 we show three cases of
the joint distribution of expression values of two genes, for
two conditions. In this Figure we are showing simulated
data for three possible changes in the co-expression of a
pair of genes in two conditions. The samples in Figure 4A
and B are drawn from a multivariate normal distribution
with μ1 = {5, 5} and μ2 = {5, 7}. For Figure A the corre-
lation between gene-pairs is ρ1 = ρ2 = 0.9 and for Figure
B it is ρ1 = ρ2 = −0.9. For Figure 4C the samples are
generated from a multivariate normal distribution with
μ1 = {5, 5} and μ2 = {5, 5} and the average correlation
between gene-pairs is ρ1 = 0.9 and ρ2 = −0.3.
In the ﬁrst two cases (Figure 4A and B) the correla-
tion of the gene-pairs show a condition speciﬁc shift, in
[56] denoted as a gap and substitution. In the third case
(Figure 4C), the gene-pairs show a reversed correlation
between the two conditions, denoted as on/oﬀ case. To
identify gene-pairs in these two types of conditions, two
scoring functions have been suggested in [56] given by:
s =
{
|ρA + ρB − αρ| gap/substitution case
|ρA − ρB| on/oﬀ case (8)
Here each of the three correlation coeﬃcients are esti-
mated for a gene-pair between gene i and j, i.e., ρA =
ρA(i, j) etc. The value of ρ corresponds to the global corre-
lation coeﬃcient of the gene-pair over the two conditions
(A,B) and ρA, ρB are the correlation coeﬃcients of the
gene-pair for condition A and condition B. In Eqn. 8, α is
a tuning parameter that governs the balance between sep-
aration and parallel alignment. In [56] it was argued to use
a value of α = 1.5. The null and alternative hypotheses
tested are:
H0 : s = 0 (9)
H1 : s = 0 (10)
In [57] the ‘expected conditional F-statistic’ (ECF-
statistic) has been introduced to measure the diﬀerential
co-expression of gene pairs (X,Y ). The method is based
on amodiﬁed F-statistic, where the variance and themean
parameter of the statistic are estimated from a mixture of
two normal distributions.
The R package R/EBcoexpress provides an empirical
Bayesian implementation to identify the diﬀerential co-
expression of gene pairs [58].
Another method called liquid association (LA) has been
proposed in [59] to identify co-expressed gene pairs. In
contrast to pairwise correlation measures, the LAmethod
considers the presence of a mediator gene, Z, for observ-
ing a co-expression between two genes at a given cellular
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state. Let X, Y and Z be gene-expression proﬁles. We say
that X and Y form a liquid association pair (LAP), if the
cellular state of X and Y is correlated with Z. The LA
score of X and Y with respect to Z is estimated from rank
transformed expression proﬁles of X, Y , Z given by
LA(X,Y |Z) = 1m
m∑
i=1
XiYiZi (11)
Here m corresponds to the number of samples. The LA
method uses a permutation test for the identiﬁcation of
signiﬁcant LA gene pair values. Due to the high computa-
tional burden of the method that would require N3 (N is
the number of genes) evaluations of Eqn 11 plus additional
permutations of the data, which is even for only N = 103
genes intractable because it requires already more than
109 evaluations. For this reason the method is only used
to (A) ﬁnd the gene Z for a given pair of genes or (B) ﬁnd
the LAP, X and Y , for a given gene Z.
Gene set and pathway analysis methods
Generally, a pathway is a group of interacting genes (a
gene set) that deploy a cellular function. In a biological
system the biological processes are coordinated functions
of sets of genes which make the organism work. Some
general pathways are, e.g., metabolic pathways, signaling
pathways or regulation pathways that represent minimal
functioning units of a cellular system. The consideration
of pathways or gene sets for a comparative gene expres-
sion analysis is an important step toward the exploration
of relevant functional mechanisms of a cell.
So far, many multivariate and univariate tests have been
proposed for a gene set analysis, see Figure 2. Find-
ing diﬀerentially expressed pathways, instead of individ-
ual genes, is not straight forward from a statistical and
biological perspective and there are several hurdles to
this approach. The ﬁrst is presented by the data them-
selves, because the number of variables is usually (much)
larger than the number of samples, i.e., n << p, that
leads to many estimation problems. The second hur-
dle is our incomplete information about the constitution
of biological pathways and the potentially high over-
lap of genes between diﬀerent pathways. For example,
databases like GO [60] provide valuable information about
genes for a large variety of diﬀerent organisms. However,
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this information is not static but continuously expanding
leaving us at the moment with a snap-shot of knowl-
edge. This makes it diﬃcult to ﬁnd precise deﬁnitions
for particular pathways of interest. The third problem
comes from the underlying gene network structure that
describes the true interactions between genes in a path-
way. Here, the problem is that as a result of such interac-
tions among genes it is usually not appropriate to assume
their independence, as frequently done for statistical
ease.
A motivating example for the general idea underlying
gene set methods is shown in Figure 3C. For condition 1
(green), the samples are drawn from a multivariate nor-
mal distribution with μ1 = {2, 2.2, 2.4, 2.6, 5, 8} and for
condition 2 (red) μ2 = {2, 7, 7.5, 2.6, 5, 8}. The covariance
matrix, 1 = 2 is for both conditions the same. In this
Figure, only 2 of the 6 gene are diﬀerentially expressed.
This reﬂects biological situations because, usually, only of
fraction of the genes belonging to a pathway is found to
be diﬀerentially expressed. However, due to the fact that
gene set methods are based on the expression of a set of
genes such methods borrow strength from the combined
analysis of the genes.
Reviews that focus entirely on gene set and pathway
analysis methods can be found in [61-65].
Null hypothesis for gene set analysis
Gene set analysis methods can be broadly divided into
two major categories, depending on what null hypothesis
is tested. The ﬁrst type of methods are called competi-
tive methods, and the second type self-contained methods
[66]. Brieﬂy, self-contained tests use only the data from a
target gene set under investigation, whereas competitive
tests use, in addition, also data outside the target gene set
(background data). In the following we describe popular
competitive and self-contained pathway methods.
Competitive gene set and pathwaymethods
In Table 1 we show an overview of gene set and pathway
methods, described in the following.
GSEA
The gene set enrichment analysis method (GSEA) [27,68]
is one of the most widely used competitive test based
method. The test uses a Kolmogorov-Smirnov test statis-
tic to identify diﬀerential expressed gene sets. The gene set
and background data set are deﬁned in the following. Let
W be the target gene set to be tested and Wc its comple-
ment in a way that the union of both sets deﬁnes all genes,
i.e., V = W ∪ Wc, in the data set. The hypotheses tested
by GSEA with respect to an enrichment score (ES) are:
H0 : ES = 0(vanishingtestscore)
H1 : ES = 0(non − vanishingtestscore)
Brieﬂy, GSEA consists of the following steps, applied to
each pathway:
(1) Estimation of gene-level test statistics.
(2) Rank ordering of the test statistics.
(3) Calculation of an enrichment score (ES) for a
pathway based on the gene-level test statistics.
(4) Permutation of the gene-labels to estimate the
signiﬁcance of the enrichment score for the pathway.
GSEArot
GSEArot (gene set enrichment analysis rotation) [70] is
very similar to GSEA, but uses a diﬀerent approach to
randomize data in order to assess the signiﬁcance of a
target pathway. More speciﬁcally, a data matrix X is ran-
domized by, ﬁrst, rotating X around a random angle δ,
resulting in a matrix X(δ). Second, from the matrix X(δ),
Table 1 Overview of diﬀerent competitive gene set methods
Principle Method Reference Test type Software
Over-representation analysis (hyper-
geometric test)
[67] parametric GOstats
GSEA [68] non-parametric GSEABase
[27] non-parametric www.broad.mit.edu/gsea
GSA [69] non-parametric http://cran.r-project.org/web/packages/GSA/
GSEArot [70] non-parametric limma
GAGE [71] parametric GAGE
PAGE [72] parametric PGSEA, GAGE
Random Set [73] parametric part of CLEAN
Generalized Random Sets [74] parametric http://GenomicsPortals.org
Gene set enrichment analysis made
simple
[75] parametric
If available, the name of the software package is provided.
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the randomization matrix is obtained by a QR decompo-
sition [76]. In [70] it is argued that this procedure has an
advantage for small sample sizes, when only very few per-
mutations are achievable from sample-label permutations.
The null hypothesis tested by GSEArot is the same as for
GSEA.
Random set
The random set method introduced in [73] is a paramet-
ric test that is a generalization of Fisher’s exact test in the
sense that enrichment scores of gene sets are compared
with randomly formed sets. The enrichment scores are
based on single gene-level test statistics reﬂecting their
diﬀerential expression.
1. Estimate the enrichment score of a target gene setW ,
s¯ = 1m
∑
i∈W
si. (12)
Here si are gene-level scores, e.g., t-scores, and
m = |W | is the number of genes in the target
pathway.
2. Estimate the enrichment score and its variance of the
background gene set V = W ∪ Wc,
μ = 1p
∑
i∈V
si, (13)
σ 2 = 1m
(p − m
p − 1
)(∑
i∈V s2i
p −
(∑
i∈V si
p
)2)
,
(14)
with p = |W ∪ Wc|.
3. Estimate the standardized enrichment score
Z = s¯ − μ
σ
. (15)
The Z score follows a standard normal distribution
under the null hypothesis H0 given by:
H0 : The target setW is not enriched for diﬀerentially
expressed genescompared withW ∪ Wc
(16)
H1 : The target setW is enriched for diﬀerentially
expressed genescompared withW ∪ Wc
(17)
It is notable that Z can be calculated without a numer-
ical randomization of the data. Further, the background
data consist of all genes V , including the ones in the target
pathwayW . In [77] this method has been applied to head
and neck and cervical cancer for human papillomaviruses-
positive and -negative samples.
GAGE
GAGE [71] (generally applicable gene set enrichment) is
also a parametric test that, similarly to GSEA, compares
the expression in a target gene set with that of the back-
ground. But instead of using a Kolmogorov-Smirnov like
test [78] it employes a two-sample t-test. The principle
steps of the method are as follows:
1. Estimate the mean fold change f and its standard
deviation σf for the m genes in the target pathwayW .
2. Estimate the mean fold change f ′ and its standard
deviation σf ′ for all p genes in the background gene
set V = W ∪ Wc.
3. Estimate the t-score:
t = f − f
′√
σ 2f /m + σ 2f ′/m
(18)
with
df = (m − 1)
(
σ 2f + σ 2f ′
)2
σ 4f + σ 4f ′
(19)
degrees of freedom.
Also GAGE employs all genes V in the background gene
set, including the ones in the target set W . The underly-
ing assumption of GAGE is that the (mean) fold changes
of genes are independent and identically distributed. The
null hypothesis tested by GAGE is:
H0 : The mean fold change of genes (MFG) in set
W is not diﬀerent to the MFG inW ∪ Wc
(20)
H1 : The mean fold change of genes (MFG) in set
W is diﬀerent to the MFG inW ∪ Wc
(21)
GSA
Another method is GSA (gene set analysis) [69]. The
method, ﬁrst, calculates z-scores, zi, with i ∈ {1, . . . ,m},
for all m genes in a given target pathway W . Then each
z-score is transformed into two scores, assessing the sign
of zi.
s+(z) = max{z, 0} (22)
s−(z) = −min{z, 0} (23)
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This results in two sets of non-zero scores S+ =
{s+(z1), . . . , s+(zm)} and S− = {s−(z1), . . . , s−(zm)} from
which their mean value is calculated,
s¯+ = mean(S+) = 1m
∑
i
s+(zi) (24)
s¯− = mean(S−) = 1m
∑
i
s−(zi) (25)
Finally, the maxmean test statistic is deﬁned by smm =
max{s¯+, s¯−}, giving the test statistic for the target pathway.
H0 : smm(W ) = smm(Wc) (26)
H1 : smm(W ) = smm(Wc) (27)
The null distribution is assessed by a restandardization,
combining a sample- and gene-label permutation.
Self-contained gene set and pathwaymethods
In Table 2 we show an overview of self-contained gene set
and pathway methods that are describe in the following in
more detail.
Sum of t-square
The sum of t-square test is an univariate test that is based
on t-scores, {ti}, individually obtained for each of the m
genes in a given set [95], see also [79]. That means that
each t-score assesses the diﬀerence of themean expression
between the two conditions,
ti = x¯i − μis¯i (28)
Table 2 Overview of self-contained gene set and pathway
methods
Principle Method Reference Software
Average of single-gene statistics [79] sigPathway
Linear Model Toolset for GSEA [80] GSEAlm
SAM-GS [81]
Globaltest [82] globaltest
GlobalANCOVA [83] GlobalAncova
Hotelling’s T2 [84-87] PCOT2
N-statistic [88] cramer
RCMAT [89]
Non-linear tests for identifying
diﬀerentially expressed genes or
genetic networks
[87]
Pathway-express [90]
Signaling Pathway Impact Analysis [91] SPIA (Bioconductor)
SEPEA [92]
PARADIGM [93]
Gene set analysis exploiting the
topology of a pathway
[94] IPS (available upon
request)
with si the pooled standard deviation. The test statistic for
a pathway is based on the individual t-scores given by
TS = 1m
√√√√ m∑
i
t2i . (29)
Because for each gene μi = 0 should hold if a gene
is not diﬀerentially expressed, the null and alternative
hypothesis can be formulated as:
H0 : TS = 0 (vanishing test score) (30)
H1 : TS = 0 (non-vanishing test score) (31)
The signiﬁcance of TS is assessed from sample-label
permuted data.
SAM-GS
The method SAM-GS (Signiﬁcance Analysis of Microar-
ray for gene sets) [81] uses the test statistics,
SAM-GS =
m∑
k=1
d2k , (32)
with dk = x¯1k−x¯2ksk+s0 . Here x¯1k and x¯2k are the samplemeans of the control and treatment condition of gene k,
sk corresponds to its pooled standard deviation and s0
is a constant for a sensitivity adjustment. The null and
alternative hypothesis can be formulated as:
H0 : SAM-GS = 0 (vanishing test score) (33)
H1 : SAM-GS = 0 (non-vanishing test score) (34)
Statistical signiﬁcance of SAM-GS is again assessed
from sample-label permuted data.
Hotelling’s T2
The Hotelling T2 test is a self-contained test that is a mul-
tivariate generalization of the univariate t-test. Its null and
alternative hypothesis can be formulated as:
H0 : μT = μC (equality in the m-dimensional
population mean vectors)
(35)
H1 : μT = μC (diﬀerence in the m-dimensional
population mean vectors)
(36)
Suppose we have two groups with nC samples from
the control group and nT samples for the treatment
group, each consisting of m genes. Let the expression
level of the ith sample of the control group and treat-
ment group be given by XCi =
(
XCi1,XCi2, . . .XCim
)t and
XTi =
(
XTi1,XTi2, . . .XTim
)t , respectively. The pooled covari-
ance matrix S is then deﬁned by
S = (nT − 1)ST + (nC − 1)SC
(nT + nC − 2) (37)
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where SC and ST are the covariance matrices for the con-
trol and treatment group. Hotelling′s T2 is deﬁned as
T2 = nT × nCnT + nC
(
μT − μC
)
S−1
(
μT − μC
)t
. (38)
The inverse of the covariance matrix is estimated via the
shrinkage estimator [96-99]. The statistical signiﬁcance
of the test statistic T2 is estimated from sample-label
permuted data.
N-statistic
The N-statistic is a non-parametric test that is used
to test the equality of two distributions. Suppose the
expression level of the ith sample of the control group,
nC , and the treatment group, nT , is given by XCi =(
XCi1,XCi2, . . .XCim
)t and XTi = (XTi1,XTi2, . . .XTim)t , respec-
tively. Let i ∈ {1 . . . nC} correspond to the control data-set
and i ∈ {1 . . . nT } to the treatment data-set. The null
and alternative hypothesis tested by the N-statistic can be
formulated as:
H0 : FC(x) = FT (x) (39)
H1 : FC(x) = FT (x) (40)
whereas FC(x) and FT (x) are twomultivariate distribution
functions from the control and the treatment condition.
The N-statistic itself is deﬁned as follows:
Nˆ =
⎡
⎣ 1
nCnT
nC∑
i=1
nT∑
j=1
2K
(
xCi , xTj
)
− 1
n2C
nC∑
i=1
nC∑
j=1
K
(
xCi , xCj
)
− 1
n2T
nT∑
i=1
nT∑
j=1
K
(
xTi , xTj
)⎤⎦
1/2
(41)
Here K
(
xCi , xTj
)
, deﬁned as K
(
xTi , xCj
)
=
∥∥∥xTi − xCj ∥∥∥2,
is the Euclidean Kernel serving as distance function
between the expression values in the two conditions.
Linear model-based pathwaymethods
There are also several approaches that utilize either a lin-
ear or a generalized linear modeling framework for a gene
set analysis. Examples for such methods are Global test
[82], Extension of GSEA [80] or GlobalAncova [83].
Topological pathway methods based on existing network
information
Some recent univariate methods, for instance, Pathway-
express [90], SPIA [91] or SEPEA [92], use instead of cor-
relation measures to estimate interactions among genes,
predeﬁned topological information as provided, e.g., by
the KEGG database [100]. These methods assign each
gene in a pathway a score that is based on the posi-
tion of a gene in the given network structure and, ﬁnally,
aggregate these individual gene scores to obtain a score
for the pathway itself. Yet another approach is provided
by PARADIGM [93]. This method uses a factor graph
model combining gene copy number variation data with
gene expression data for the identiﬁcation of diﬀerentially
expressed pathways.
Iterative Proportional Scaling: IPS
IPS (Iterative Proportional Scaling) [94,101] is another
method that utilizes the topology of pathways of a given
gene set by testing the hypotheses:
H0 : −1c1 = −1c2 :assuming−1c1 ,−1c2 ∈ S+(G) (42)
H1 : −1c1 = −1c2 :assuming−1c1 ,−1c2 ∈ S+(G) (43)
In this method, the covariance matrices, c1 ,c2 , are
estimated from the data, for both conditions, using the
Iterative Proportional Scaling (IPS) algorithm. The inverse
of the estimated covariance matrices are positive deﬁnite
(concentration) matrices for which it is assumed that the
non-zero elements in −1c1 and 
−1
c2 are identical; this is
the meaning of −1c1 ,
−1
c2 ∈ S+(G) where S+ indicates
the class of all symmetric positive deﬁnite matrices with
non-zeros elements given by the binary matrix G. This
means that the concentration matrices, −1c1 and 
−1
c2 ,
have identical zero element, but are allowed to have dif-
ferent non-zero entries. In other words, it is assumed that
the underlying topology of a pathway is the same for con-
dition c1 and c2, given by G, whereas Gij = 0 corresponds
to an ‘absent’ interactions among the genes i and j. Since
the structure ofG is not estimated from the data, it is nec-
essary to obtain it from an independent source, e.g., from
the KEGG database or Reactome [100,102]. In [94] it is
shown that a log likelihood (log(	)) ratio test can be used
to test for the equality of the concentration matrices for
the two conditions and that asymptotically the log likeli-
hood ratio follows a Chi-square distribution with r + m
degrees of freedom, i.e., log(	) ∼ χ2r+m, whereas m is
the number of genes in the pathway and r is the number
of non-vanishing edges in G corresponding to the ﬁxed
interaction structure of the pathway.
The IPS method has been used in [94] to study acute
lymphocytic leukemia with and without BCR/ABL gene
rearrangement. As a result, the JUN oncogene with
RAS/MAPK/JNK followed by NFAT and NFKB seem to
be crucial in distinguishing BCR/ABL positive and nega-
tive patients.
Diﬀerential correlation/interactionmethods
In the previous sections, we discussed diﬀerent gene set
and pathway-based methods for the identiﬁcation of dif-
ferentially expressed pathways. These methods focused
either only on the expression of genes, or considered an
underlying interaction topology among the genes as taken
from an independent source. However, even when these
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methods considered an underlying network structure, this
structure was assumed to be the same for the ‘treatment’
and ‘control’ group.
In contrast, in this section we discuss methods that esti-
mate the correlation/interaction structure of the genes
within pathways, for each experimental condition. The
underlying rationale for these approaches is to assume
that the expression proﬁles of genes are dependent on
each other [103,104] as the genes in a pathway inter-
act, either directly or indirectly [105]. This assumption
results from the observation that genes with similar func-
tions or cellular localization are often co-expressed and
cluster together. The methods discussed in this section
bear a similarity to the statistical methods for the esti-
mation of diﬀerential correlated gene-pairs (see section
‘Gene-pair analysis’). However, the extension of such
gene-pair measures to the pathway level allows the iden-
tiﬁcation of pathways that show, e.g., a condition speciﬁc
correlation change.
In Figure 3E we show a simulated example scenario
for condition speciﬁc correlation changes of the expres-
sion proﬁles for a gene set. In Figure 3E the correlation
between all gene-pairs of a gene set is aggregated by
a summary statistic. In this example, the mean values
between the genes is of a comparable order, whereas the
correlation of the gene set in the treatment condition is
reduced.
A variety of diﬀerent pathway methods have been devel-
oped that integrate the estimated gene correlations or
co-expression structures with gene expression data. A
summary of diﬀerent methods that are used for the iden-
tiﬁcation of diﬀerential correlation/interaction changes
in pathways is shown in Table 3. In the following these
methods are described in more detail.
Graph Edit Distance: GED
Among the ﬁrst approaches that estimate the interaction
structure for a pathway analysis to identify diﬀerentially
correlated pathways (DCP) is a method introduced in
[106]. This method uses the graph edit distance (GED)
score as a test statistic.
More precisely, for a given pathway containing m genes
an association graph, G, also called pseudo-pathway, is
inferred for each condition. That means the resulting
network comprises the m genes of this pathway only.
The inference method estimates correlation and partial
correlation coeﬃcients and tests their statistical signif-
icance. That means, if either the correlation or partial
correlation coeﬃcient for two genes i and j in this path-
way vanishes, then the resulting network will not have an
interaction between gene i and j, i.e., Eij = 0, otherwise
there is an interaction, Eij = 1. Here E corresponds to the
adjacency matrix of the network. SupposeGc1 andGc2 are
two networks that have been inferred from gene expres-
sion data for condition c1 and c2. Further, assume that
M1,M2, . . . ,Mn are all possible transformations that map
Gc1 into Gc2 , i.e, Mi(Gc1) = Gc2 . Then the optimal cost
of the optimal transformation, M′, is given by c(M′) =
min {c(Mi)|1 ≤ i ≤ n}. This value is used to deﬁne a dis-
similarity measure dGED(Gc1 ,Gc2) = c(M′) between the
two networks Gc1 and Gc2 , called the graph edit distance
(GED) score [112]. For arbitrary networks, Gc1 and Gc2 ,
the estimation of dGED(GA,GB) is numerically challeng-
ing. However, for our speciﬁc problem it can be eﬃciently
calculated based on the adjacency matrices, Ec1 and Ec2 ,
of the two networks,
dGED(Gc1 ,Gc2) =
2
m(m − 1)
m∑
ij
∣∣∣Ec1ij − Ec2ij ∣∣∣ . (44)
In [106] the GED score has been used as a test-statistic
for the formulation of the hypotheses:
H0 : dGED(Gc1 ,Gc2) = 0 (45)
H1 : dGED(Gc1 ,Gc2) = 0 (46)
In order to assess statistical signiﬁcance, sample label
permutations are performed to obtain the null distribu-
tion.
Extensions of this method can be found in [113] where
mutual information values have been used to capture non-
linear relations among gene expression values. Further, in
[114] a methods based on a relevance value (RV) has been
deﬁned for integrating diﬀerent types of genomics data
sets which has also a resemblance to the GED.
Table 3 Overview of methods for the identiﬁcation of diﬀerential correlation/interaction changes in pathways
Principle Method Reference Software
Graph edit distance [106]
Gene-set co-expression analysis (GSCA) [107] GSCA (http://www.biostat.wisc.edu/∼kendzior/GSCA/)
Diﬀerential co-expression (dCoxS) between gene-sets [108] dCoxS (http://www.snubi.org/publication/dCoxS/index.html)
DiﬀCoEx [109] R code is provided in the paper
Diﬀerential disease network using C3NET [106,110] c3net (http://cran.r-project.org/web/packages/c3net/index.html)
Disease associated interactions using Synergy network [111] MATLAB code is provided in the paper
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Gene set co-expression analysis: GSCA
A method that is based on (zero-order) correlation coeﬃ-
cients is gene set co-expression analysis (GSCA) [107]. This
method uses as test statistic the dispersion index, which is
deﬁned as follows:
Ds(ρc1 , ρc2) =
√√√√ 1
P
P∑
k=1
(
ρ
c1
k − ρc2k
)2 (47)
Here ρck , with c ∈ {c1, c2}, is the k-th correlation coeﬃ-
cient for a gene pair, which can be formed among the total
number, P = (m2 ), of such pairs for a pathway consisting of
m genes. The null and alternative hypotheses tested are:
H0 : Ds(ρc1 , ρc2) = 0 (48)
H1 : Ds(ρc1 , ρc2) = 0 (49)
From the deﬁnition of the dispersion index follows that
also this method aims at detecting at diﬀerential cor-
relation among pathways, despite its name emphasizing
co-expression. Interestingly, the dispersion index corre-
sponds to the GED score if its components in Eqn. 47
are re-labeled and one deﬁnes the components of the
adjacency matrices Ec1 ,Ec2 as the correlation coeﬃcients
rather than the outcome of the hypotheses tests [106].
A visualization of the underlying idea of GSCA is
shown in Figure 3E. The gene expression values are sam-
pled frommultivariate normal distributionN(μ1,1) and
N(μ2,2) with μ1 = μ2, and the average covariance
between gene-pairs is 1 = 0.8 and 2 = −0.2. Despite
the fact that there is neither a diﬀerence in the individ-
ual expression of genes nor the the expression of a set of
genes, condition 1 and 2 can be distinguished by using a
measure based on a correlation change.
Partial least squares based scores: PLS
A statistical framework based on a partial least squares
score is proposed in [115]. Similar to the above methods,
two matrices for the two conditions are inferred. These
matrices can be seen as weighted networks, whereas an
edge weight corresponds to the strength of the association
between two genes. In this paper, three diﬀerent types of
tests are introduced that allow (A) testing for changes in
the module structure of the two networks, (B) testing for
changed in the connectivity of a particular gene set, and
(C) testing for changes in the connectivity of a particular
gene.
Diﬀerentially co-expressed gene sets: dCoxS
In [108] the diﬀerentially co-expressed gene sets (dCoxS)
algorithm is proposed. This is an entropy-based method
that uses the interaction score (IS) to measure the dif-
ference between two pathways. The IS is estimated by
the correlation coeﬃcient between the entropies of the
two pathways. The entropies themselves are estimated by
using the Re´nyi relative entropy, which is deﬁned by:
Dα(P ‖ Q)= 1
α − 1 log
(∫ (
pαq1−α
)
dp dq
)
≈ log fˆh(Si)
fˆh(Sj)
(50)
Here α is a parameter and fˆh(Si) and fˆh(Sj) are expres-
sion densities of the samples i and j, estimated by using
a multiplicative kernel for the density estimation. Further,
p and q are the probability density functions of P and Q.
From this, the IS is estimated by:
IS =
∑
i<j(REP1 − R¯EP2)(REP1 − R¯EP2)√∑
i<j(REP1 − R¯EP1)2
√∑
i<j(REP2 − R¯EP2)2
.
(51)
In this equation, REP1 and REP2 are entropy matrices
of two gene sets, P1 and P2, for condition ci, whereas
each component of the entropy matrices is proportional
to ∼ log fˆh(Si)
fˆh(Sj)
. That means, strictly IS = IS(P1(ci),P2(ci)).
Application of Fisher′s Z-transformation to IS results in
a z-score, z
(
IS(P1(ci),P2(ci))
)
, for condition ci. Combi-
nation of both z-scores for condition c1 and c2 leads to,
zcomb =
z
(
IS
(
P1(c1),P2(c1)
))
− z
(
IS
(
P1(c2),P2(c2)
))
√
1/(n1 − 3) + 1/(n2 − 3) .
(52)
Here n1 and n2 correspond to the number of samples
for condition c1 and c2. The interpretation of the null
hypothesis tested can be stated as:
H0 : zcomb = 0 (equality in entropy changes between
gene-pairs in the pathways P1 and P2
between the conditions c1 and c2)
(53)
H1 : zcomb = 0 (diﬀerence in entropy changes between
gene-pairs in the pathways P1 and P2
between the conditions c1 and c2)
(54)
In [108] dCoxS has been applied to gene expression data
from lung cancer. Their analysis identiﬁed the Thrombin
signaling and protease-activated receptors pathway, which
is known to be involved in the angiogenesis of lung cancer,
as the most frequently changed pathway. Another inter-
esting result found is that all signiﬁcant pathway pairs had
a lower interaction score in lung cancer than in the normal
control group. This might indicate that the variability in
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form of exploited parallel pathways is in cancer lower than
in normal cells.
Gene regulatory networks
Finally, we would like to mention that also gene regula-
tory network inference methods have also been used in
this context. More precisely, several attempts have been
made to identify disease networks [110,111] that corre-
sponds to particular pathways. For instance, in [110] the
C3NET inference method [116,117] has been used to infer
pathway speciﬁc networks for prostate cancer. A struc-
tural comparison between the pathway-speciﬁc networks,
similar to [106] which is based on testing the hypothesis in
Eqn. 45, allowed to identify growth and cell cycle related
pathways.
On a side note, we would like to add that Gaussian
graphical models (GGM), also known as Markov random
ﬁelds [118-120], are also frequently used to infer gene reg-
ulatory networks. This model assumes that all variables
follow a multivariate normal distribution with a speciﬁc
structure of the inverse of the covariance matrix,  =
−1, whereas  is called the precision or concentration
matrix. Network inference methods based on GGMmake
use of the relation,
ρij|V\{ij} = − ωij√
ωiiωjj
, (55)
connecting the partial correlation coeﬃcient of full-order
(LHS) with the elements of,ωij ∈ . The partial correla-
tion is of full-order (with respect to the number of genes)
because V\{ij} is the set of all genes excluding i and j, i.e.,
the largest possible set of genes not considering i and j.
Several methodological improvements have been sug-
gested to infer gene regulatory networks based on GGM
[121-123]. These methods diﬀer in the way the inverse of
the covariance matrix, −1, is estimated and in the sta-
tistical tests employed to assess signiﬁcance. The reason
for these technical variants comes from a variety of prob-
lems. For instance, if the number of samples is smaller
than the number of genes, which is typically the case
for a microarray data set, the sample covariance matrix
is not positive deﬁnite and, hence, not invertible. This
means that Eqn. 55 cannot be exploited. In order to over-
come such practical estimation problems, recently, several
extensions based on the LASSO (least absolute shrinkage
and selection operator) have been suggested [124-128].
Importance of multiple hypotheses testing and
sample size: An example for diﬀerentially
expressed genes
Typical microarray experiments measure the concentra-
tion of thousands of mRNAs simultaneously. For this
reason, usually, one does not just test one statistical
hypotheses but dozens, hundreds or even thousands. This
makes it mandatory to control the overall error rate for
all the tests, because the probability to make at least one
error, Pr(V ≥ 1|α, t) = (1 − (1 − α)t), for a test with a
false positive rate of α, increases rapidly with the number
of tests t, as can be seen in Figure 5. Here, V corresponds
to the number of false positives. From this one can see
that even for a moderate number of tested hypotheses,
e.g., 300, this probability is already almost 100%. Hence,
each of the three principle types of hypotheses tests dis-
cussed in the previous sections are severely eﬀected by
this problem.
Classically, a Bonferroni correction is used controlling
the Family wise Error Rate (FWER) [129,130],
FWER(α) = P(V ≥ 1). (56)
Unfortunately, this method is often too stringent, which
may give no signiﬁcant results at all. For this reason, alter-
native error measures and control procedures have been
introduced. A recent, very popular measure is the false
discovery rate (FDR) [131],
FDR =
{
E[V/R] if R > 0
0 if R = 0.
}
(57)
controlled by a procedure introduced by Benjamini &
Hochberg (BH) [131]. Subsequently, various related error
measures have been proposed like pFDR [132], local
FDR [133,134] and a variety of other control procedures
[129,135]. Also extensions have been suggested [136] that
0 200 400 600 800 1000
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
number of independent tests (t)
pr
o
ba
bi
lit
y 
of
 s
el
ec
tin
g 
at
 le
as
t o
ne
 fa
ls
e 
po
si
tiv
e
Figure 5 Dependence of Pr(V ≥ 1|α = 0.01, t) on the number t
of tested hypotheses.
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allow the control of an error measure in cases where the
underlying tests are not independent from each other.
This is particularly important for microarray data that
contain a none neglectable correlation structure among
the genes.
In order to demonstrate the importance and the inﬂu-
ence of diﬀerent error measures and control procedures,
we provide a numerical example, shown in Figure 6. Here,
‘BH’ means the Benjamini & Hochberg procedure to con-
trol the FDR [131], ‘pFDR’ indicates the positive false pos-
itive rate controlled with a method introduced in [132],
‘Bonferroni’ corresponds to the FWER controlled with a
Bonferroni correction and ‘localFDR’ corresponds to the
local FDR [134,137]. The local FDR is deﬁned as,
localFDR = Prob(null |test statistic). (58)
that means the local FDR is the probability that the null
model is true conditioned on the observed test statistic.
The data we used for this analysis correspond to simulated
gene expression data sampled from a normal distribution
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with diﬀerent mean values for the two conditions. More
precisely, we simulate 2000 genes of which 400 are dif-
ferentially expressed (true positives). Further, we study
three diﬀerent (constant) correlation structures with ρ =
{0.0, 0.2, 0.5}. The results shown in Figure 6 are for each
sample size averaged over 50 independent runs.
As one can see, ‘BH’ and ‘pFDR’ give more signiﬁcant
results and, hence, have a higher power than the Bonfer-
roni correction and the local FDR when there is either no
or only amoderate correlation among the genes. However,
it is important to note that the utility of these methods
depends on the characteristics of the data. For example, if
the average correlation in the data is ρ = 0.0, then ‘pFDR’
tends to perform best (see Figure 6A). However, when the
average correlation in the data increases (ρ = 0.5) then
the ‘localFDR’ [134,137] becomes preferable. We want to
note, for a sample size of 5, the power of the methods is
usually very low because only a couple of genes test sig-
niﬁcant. In addition, a large fraction of these can be false
positives. This seems to be especially for the local FDR
method a problem.
Recommendations
In general, there is a trade-oﬀ between a high power of
a statistical method on one side, which requires a large
number of samples, and low experimental costs on the
other. For the identiﬁcation of diﬀerentially expressed
genes the results in Figure 6 provide some guidelines. Even
for the most favorable condition (for ρ = 0.0) a study will
usually be underpowered for ≤ 20 samples, however, on
the other hand, even for 10 samples the Type I error will
be well-controlled.
For gene set and pathway-based methods such recom-
mendation are more delicate. In [105] two self-contained
(sum of t-square and Hotelling’s T2 [84,95]) and one com-
petitive test (GSEA [27]) have been analyzed. As a results,
it is suggested not to apply a method unconditionally to
all pathways in a given data set, but to ﬁlter them in order
to eliminate conditions for which a method is more likely
to cause problems. This can be seen as a reﬂection of the
heterogeneity of cancer, as discussed above in the section
‘Gene expression data and cancer’.
In [105] it has been suggested to ﬁlter pathways accord-
ing to the following criteria: Hotelling’s T2 should only be
applied to pathways with less than 35 genes and a sample
size larger than 30. The sum of t-square test should only
be used for pathways with DC > 10% (DC is detection
call; the percentage of diﬀerentially expressed genes in a
pathway) and a sample size of 25 or larger. GSEA should
only be used for pathways with DC > 10% and a sample
size larger than 25. That means for the sum of t-square test
and GSEA, at least 10% of the genes in a pathway should
be diﬀerentially expressed for the method to work. How-
ever, this is not independent of the correlation structure
of the data. In general, in the presence of high correla-
tions a larger number of diﬀerentially expressed genes is
beneﬁcial for these methods.
It is important to emphasize that these sample sizes
are diﬀerent to the minimal sample sizes necessary in
order to avoid in addition that a study is underpowered.
For the minimal sample sizes [105] predict a sample size
of 59 for Hotelling’s T2 and 57 for the sum of t-square
test and 83 for GSEA. Further, in [95] it was found that
using the N-statistic with 40 samples (or more) leads to a
good control of the Type I error and a satisfactory power
for a variety of diﬀering conditions, including diﬀerent
correlations of the data and DC values in the pathways.
Further studies reviewing related methods can found in
[61,62,65,139,140].
We would like to emphasize that the above recommen-
dations are data dependent. That means it is not possible
to judge solely based on the number of samples which
method to use. Instead, one needs to estimate charac-
teristics from a particular data set in order to select an
appropriate test. This implies, e.g., to estimate the cor-
relation structure and the detection call. In the context
of cancer there is an additional problem that needs to
be considered. It is known that a tumor is a heteroge-
neous collection of cells rather than a homogeneous one
[26,141]. This translates into the heterogeneity of gene
expression data [142] making it even more dangerous to
provide general recommendations without considering a
particular data set.
On a general note, we would like to highlight that when-
ever a given data set allows to (I) identify changes in single
genes, (II) identify changes in gene sets or pathways, and
(III) identify changes in the correlation structure in path-
ways, thenmethods from each of the three categories (I-III)
should be applied and there is no need to focus on just
one of these. The reason for this is that despite the fact
that gene set or pathway methods have more explanatory
power than methods to identify changes in single genes
[64,95] it does not mean that there are no conditions for
which single gene methods reveal interesting biological
information that may not be obtained by the other types
of methods. For instance, the diﬀerential expression of a
single gene based on changes in the mean (rather than the
variance) may be an indicator for the presence of a sin-
gle signaling chain rather than of many parallel pathways.
Hence, this could provide information about the presence
of a Mendelian trait or a complex trait that contains a
strong monogenetic component. It appears that for such
conditions single gene methods have an advantage over
gene set or pathway methods, although, the latter meth-
ods may be adaptable to such question as well. However,
this may require additional eﬀort. In summary, we rec-
ommend to use all diﬀerent approaches (I-III) side-by side,
whenever this is permitted by the data, to interrogate the
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data in the broadest way, because this translates into a
diverse set of diﬀerent biological questions.
Our recommendation complements a common line of
thought asking for the combination of diﬀerent types of
data. Although it is certainly true that combining diﬀerent
types of high-throughput data, e.g., fromDNAmicroarray
and ChIP-chip experiments, is in general more informa-
tive, it is also more time and cost intensive to generate
such data combinations. For this reason, frequently, only
gene expression data are available. Hence, our review pro-
vides a survey of method to get the most out of expression
data sets.
Finally, we would like to emphasize that all methods
require an appropriate ﬁltering and normalization of the
data in order to obtain robust and statistically sensible
results [143,144].
Conclusions and discussion
In the post genomic era, biology transitioned from a
‘gene-centric’ to a systems-focused ﬁeld. This change is
also reﬂected in the transition from methods to identify
‘diﬀerentially expressed single genes’ to approaches for
ﬁnding ‘diﬀerentially changed pathways’. Such a transition
is natural, because a systems view is required to under-
stand the complex biological functions inside a cell that
are responsible for the observable phenotypic outcomes
[9,11,145].
As recent ﬁndings in cancer research demonstrate,
cancer is a heterogeneous disorder, even within a par-
ticular cancer type. For example, breast cancer is cur-
rently subcategorized into four major tumor subtypes
[146]: basal-like, HER2-enriched, luminal (which can be
further reduced) and normal-like tumors. Considering
the fact that these results have been achieved by using
high-throughput data one can expect further reﬁnements
when data from diﬀerent hight-throughput technologies
become available and being combined with each other. For
this reason, it appears sensible to assume such a hetero-
geneity not only on the global, phenotype level, but also
within the cells, on the pathway-level. This implies that a
pathway-based ﬁltering, as suggested in [105], is necessary
to apply a method only selectively, and not unconditional,
to cancer pathways.
Regarding potential future directions, we expect to see
an increase in methods that target changes in the cor-
relation structure in pathways for three reasons. First,
genes and their products do interact with each other. This
implies that there exists a correlation structure among
these entities that represents, potentially, useful biolog-
ical information that may be missed by co-expression
based methods [106]. Second, the costs to generate high-
throughput data are declining, which makes it easier for
the experimenter to generate a suﬃciently large number
of samples that enables such an analysis. This is an impor-
tant point, since the required sample sizes for a pathway
analysis is considerably larger than for single gene analy-
ses. Third, biologically, the hallmarks of cancer point to a
few pathways as pivotal elements in themolecular elucida-
tion of carcinogenesis, e.g., Wnt/Notch signaling, Hedge-
hog signaling or DNA damage control [147-149]. Hence,
semantically, pathway studies enable the systematic con-
nection of oncogenes, tumor-suppressor genes and stabil-
ity genes [150] to provide fundamental insights into causal
mechanisms underlying cancer. Unfortunately, the tempo-
rary literature especially of methodological papers discuss
their results rarely in the framework of the hallmark path-
ways. For this reason, we suggest that future studies aim
for a conceptual discussion of their results within this
enlightening framework. Not because it provides the ﬁnal
answers to understand cancer [151], but due to the fact
that it enables a systematic approach to the emperor of all
maladies [152].
Reviewers’ comments
First of all, we would like to thank all referees for their
fruitful suggestions and comments. In the following, we
kept our answers to the raised issues short but included
our responses in the main text.
Referee 1: Dr. Arcady Mushegian
The manuscript by Emmert-Streib and colleagues is a
review of statistical methods for analysis of gene expres-
sion data, but it is also muchmore than that. It is relatively
rare for the statisticians to review all classes of such meth-
ods and to give an eminently logical classiﬁcation not only
of the techniques on which the methods are based, but
also of the kinds of questions that are asked when applying
these methods. This, certainly, is a strength of the work
and the reason why it should appeal to the biologists that
would like to have a deeper insight into which methods
are appropriate to which task at hand.
I have, however, several comments that rank somewhere
between suggestions and concerns. Most importantly, the
authors propose to distinguish three groups of meth-
ods: those that identify changes in single genes, those
that identify changes in gene sets or pathways, and those
that identify changes in the correlation structure in path-
ways. (By the way, in the Abstract and elsewhere, the
description of the groups is almost the same as above,
but “changes” are substituted by “diﬀerential changes” -
is it not a tautology, in particular when there are only
two samples?). Then, in discussing the ﬁrst two classes of
methods, the authors almost in every case give a clear for-
mulation of the question that is being asked of the data,
in the form of the statistical hypothesis about the data
that is being tested. This is an excellent way of explain-
ing things. Unfortunately, it is not consistently applied:
Emmert-Streib et al. Biology Direct 2012, 7:44 Page 19 of 25
http://www.biology-direct.com/content/7/1/44
even among these classes of methods, the hypotheses are
not mentioned, and then, upon discussing the diﬀerential-
correlation methods (pp. 15-18), the hypotheses are not
explicated at all, except for the IPS method. I think this
need to be changed, and the null hypotheses need to be
stated for all methods for which this is possible; and if the
framework is such that no explicit null hypothesis exist,
this needs to be discussed, and the applicable intuitive
formulation be given.
Reply:
We appreciate this suggestion and added to all methods
the deﬁnition of their null hypothesis. In addition, we
extended the discussion in section ‘Formulating biologi-
cal hypotheses’ explaining why it can be diﬃcult to ﬁnd a
biological interpretation for a null hypothesis and we oﬀer
some explanation for this.
Question:
My other concern is abut Figures 3 and 4. The authors
never state what the data points there represent. They
must be expression values for two genes, but how are these
data collected - are they technical replicates? biological
replicates? some kind of ordered series? unordered series
such as for example diﬀerent drug treatments? Does it
matter what of the above they are?
Reply:
We added an explanation of the data, which are simu-
lated data to visualize the principle idea underlying some
methods, to the corresponding methods.
Question:
The third shortcoming of the paper is that there is a signif-
icant disconnect between well-covered methodology and
the stated goal of discussing the application to cancer biol-
ogy. In fact, the short discussion about cancer hallmarks is
an excellent introduction that points out the way in which
analysis of gene expression can lead to the understand-
ing of changes in expression of particular (“hallmark”)
pathways. This theme, however, is not followed through.
Though occasionally we read that such and such method
was applied to analysis of a particular type of cancer,
there is never any discussion of what was found in gene
expression data that allowed an insight into cancer biol-
ogy. What happens to the hallmark pathways at the level
of gene expression programs? Which methods have been
used to support (or maybe question?) which aspects of the
hallmark hypothesis? Which pathways were predicted or
shown to be diﬀerentially regulated at the transcription or
mRNA concentration level?
Reply:
We agree with the reviewer that ‘Which methods have
been used to support (or maybe question?) which aspects
of the hallmark hypothesis? ’ is an important questions.
Unfortunately, the methodology oriented literature does
rarely touch this topic in a clear manner. That means
in order to extend the paper in this direction we could
not survey these issues but would need to establish such
results. Instead, the concern in our paper is to propa-
gate such an approach in the context of the presented
methods. A discussion has been added to ‘Discussion and
conclusions’.
Question:
Finally, there is the question of, if you will, general biol-
ogy of transcriptional response. It stands to reason, and
indeed has been occasionally shown, that in order for a
pathway to be regulated, it may not be necessary to reg-
ulate all its components at the same (in this case, mRNA
concentration) level. One may ﬁnd that the gene prod-
uct amounts are regulated at diﬀerent levels, or maybe
even only one or a few, e.g., rate-limiting, components
are regulated at all. This would argue that single gene-
based methods may in these cases provide a better clue to
the process than pathway-based or gene set enrichment-
based methods. It would be interesting to know whether
this has been observed in the cancer datasets. A related
question is about the rules of thumb in pathway analysis:
for example, if a typical pathway (network module?) has a
size of N genes, what is the number of genes in this path-
way m < N that would still register as an enrichment in
some of the tests that the authors discuss?
Reply:
This is an important point. We included a discussion of
this to section ‘Recommendations’. We added also a dis-
cussion of the danger of general suggestions and motivate
this by known characteristics of gene expression data from
cancer. The problem is twofold. First, each method has its
own characteristics under what conditions it works best.
Second, data sets from cancer are very heterogeneous so
that two data sets containing about the same number of
samples can exhibit a very diﬀerent correlation structure
and expression patterns. This holds potentially also for
diﬀerent grades of one cancer type.
Regarding the ﬁrst question, it appears to us that this
is related to the presence or absence of parallel pathways
conveying a molecular signal. If for example no paral-
lel pathways exist the detection of diﬀerentially expressed
genes can provide a robust way to detect functional
changes. On the other hand, if there are many alter-
natives this may not be the case and gene set meth-
ods appear to be better suited for such a situation. In
general, this kind of cross-method comparisons are not
well studied and we are not aware that this has been
systematically addressed for cancer or other data sets.
One reason for this is that until recently, most data sets
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contained less than 20 samples per condition, which usu-
ally does not permit a robust analysis of gene set or
pathway methods and once larger data sets became avail-
able the detection of diﬀerentially expressed genes was
neglected, potentially, due to the erroneous assumption
that diﬀerentially expressed gene set methods include the
former tests.
In order to emphasize that it is desirable to apply meth-
ods from all three diﬀerent levels simultaneously ((I) iden-
tify changes in single genes, (II) identify changes in gene
sets or pathways, and (III) identify changes in the corre-
lation structure in pathways) whenever a given data sets
allows this, rather than to focus on just one of these levels,
we added a discussion to section ‘Recommendations’.
Thank you for your suggestions and comments.
Referee 2: Dr. Byung-Soo Kim
General comments This is a well organized review of
recent statistical methods of analyzing microarray exper-
iment data sets, particularly on cancers, from single gene
analysis to identifying diﬀerential changes in pathway, and
ﬁnally to comparing a given pathway under two diﬀer-
ent conditions. However, I would like to indicate following
four points for the possible improvement. (1) Gaussian
graphical model: From the methodological point of view,
it is desired to include the sparse Gaussian graphical
model (GGM) approach for estimating the gene net-
work under the multivariate normal assumption from a
microarray data set. For the recent development of GGM
approach one can include glasso (Friedman, Hastie and
Tibshirani, 2008; Witten, Friedman and Simon, 2011)
[125,127], SCAD penalty of Fan, Feng and Wu (2009)
[124], adaptive lasso of Zou (2006) [128] and Kiiveri (2012)
[126], among others. (2) Eﬀect of inter-gene correlations
on the single gene analysis. A series of Efron’s recent
work (Efron 2007a, 2007b) [134,137] discussed in detail on
how inter-gene correlations could aﬀect the detection of
diﬀerentially expressed (DE) genes in a single gene anal-
ysis? By including Efron’s recent work and his R package
“locfdr” authors can show how FDR can be used in the
real data analysis in their Section on “Importance of mul-
tiple hypotheses testing and sample size: An example for
diﬀerentially expressed genes”. (3) Some of the reviews
are misleading. These are the few examples. (i) The sen-
tence, at the middle of page 12, “However, in order to
use a two-sample t-test with equal size of the two sam-
ples it is assumed that the mean fold change f ’ and its
standard deviation σf would be the same for a randomly
selected background set consisting of only m genes, see
Eqn. 10”. Actually ([99], Luo et al., 2009) assumes the i.i.d
of the fold change of genes to make Eqn 10 have a t
distribution. Here the key assumption was the indepen-
dence, which wasmissing in the aforementioned sentence.
(ii) p. 14. Eqn 16. In ([126], Tian et al., 2005) no t-square
statistic was employed. (iii) Eqn 24 of p. 18 does not make
sense. Authors of ([20], Cho et al., 2009) didn’t make it
clear in their equation (3) what Renyi entropy was when
the underlying random variables were continuous. (iv) I
would suggest authors to allocate more space on the work
of ([90], Massa et al, 2010) which was methodologically
sound and deserve more coverage than just the IPS algo-
rithm. (4) Inconsistency of notations. In page 11 authors
deﬁned p and m to be sizes of the background genes and
a target gene set, respectively. However, in line 2 of page
15 “p genes” (which should have been m genes accord-
ing to page 11 deﬁnition) was incorrectly labeled. This
inconsistency was repeated in N-statistic section of p.15,
and also in Eqn 16 in p. 14 and Eqn 22 of p. 17. The
“p-dimensional...” should be “m-dimensional...” at the bot-
tom two lines of p. 14.
Minor Comments
1. p.2 “Gene expression data from next generation
sequencing (RNA-seq)”. This is an important issue.
There is no direct relevance, however, with statistical
methods reviewed in this paper.
2. p.4. For detecting diﬀerential correlation and
diﬀerential variance, it would be better to explain
why these approaches were taken. For example, in
([54], Ho et al., 2008) it was clearly indicated that
changes in expression variability were associated
with changes in coexpression pattern, which implied
that DV was a signal rather than a noise.
3. Legend of Figure 2. “The data is...” should be “The
data are... ”.
4. p.7. There is no reference of Figures A, B in the main
text. Also indicate in the legend of Figure 3 what  is
in Figure 3E.
5. p.8. In the legend of Figure 4 what the symbols in the
outer-panel represent? What do the lines represent?
It is better to use diﬀerent notation (A, B) to avoid
confusion in the main text of the second paragraph
of p. 9.
6. p.9 What is “alpha” in Equation (4)?
7. p.9 line -9. You may include two speciﬁc patterns of
dependence of two genes, namely, type A dependence
of Klevanov, Jordan and Yakovlev (2006), and hidden
regulator dependence of Lim, Kim and Kim (2011).
8. p.15 line -13. “euclidean Kernel” should be
“Euclidean kernel” (9)
9. p.15 line -10. “a either” should be “either”.
10. p.15 line -8. Author may want to include Tsai and
Chen (2009) for another reference of Hotelling’s
T-square statistic.
11. p.17. line 15, What are “A” and “B”?
12. p. 18 line 2. Better to include Lauritzen (1996) as a
reference of IPS algorithm.
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13. p. 22. It would be more beneﬁcial for the read to
move the last paragraph of p. 22 (extended to p. 23)
to Introduction section.
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Reply:
We revised our text correspondingly and addressed all
your suggestions. We would like to point out that the
major goal of our review is not a full coverage of statistical
details but to provide suﬃcient information for the reader
to acquire a basic understanding of major principles and
assumptions that underly the methods. The problem is
that if too many detail are presented the paper would
turn quickly into a formal description which may not be
appreciated by a biology oriented readership.
Minor Comments
1. p.12. line 1: What is N?
2. p. 15. line -7 -5: “two i.i.d samples of genes...” is rather
confusing. Luo et al. (2005) assumed the i.i.d of the
fold change of genes, which was much stronger than
just assuming equal mean and variance. It is better to
rewrite this sentence to convey the original material.
3. p.17. line -1: “p genes” should be “m genes”.
4. p.22. Eqn. (50): What are p and q?What are Si and Sj ?
5. p.37. Reference 30, p. 38. References 40, 59; The
journal title should be consistent with Reference 27
or vise versa.
6. p.40. References 90, 108: Location of the publisher is
missing.
7. p.40. References 93,94; The journal title should be
consistent with Reference 119.
8. p.40. Reference 109: Author was duplicated at the
end. The location and the publisher were missing.
9. p.41. Reference 117. The article title is missing.
10. p.41. Reference 118: The location of the publisher is
missing.
11. p.41. Reference 133. The journal title should be
consistent with Reference 27.
Reply:
All comments have been addressed and we revised the
main text correspondingly.
Thank you for your suggestions and comments.
Referee 3: Dr. Joel Bader
This manuscript reviews methods for analyzing gene
expression data with tests of individual genes, gene pairs,
gene sets, and networks. The manuscript is strong in cov-
ering many methods. It would be more helpful if the
authors also provided a point of view or evaluation of
methods. Can anything be said about the relative power
of diﬀerent approaches, or which have proven to be
more useful in practice? What about the tradeoﬀ between
robustness, power, and speed for realistic data? Most of
the discussion of method choice is generally about sam-
ple size requirements for all methods rather than method
choice given sample size. The two parts of the manuscript,
gene expression and cancer, don’t really mesh. Most of the
methods review is not cancer speciﬁc. Possibly of greater
relevance to cancer are methods that combine diﬀerent
types of data.
The manuscript is generally well written and easy to
understand, with ample references to the original work
and to previous reviews.
Minor corrections
1. p. 1 ‘one gene, − > should be ‘ for open-quote in
latex, here and elsewhere
2. p. 2 diﬀernt microarray − > spelling
3. p. 2 comprises, e.g., mRNAs − > ‘e.g.’ doesn’t sound
right here. How about providing a full list: mRNA,
tRNA, rRNA, and short regulatory RNAs
4. p. 2 ‘In the third step the reads are mapped to known
exon sequences of genes.’ Are there also de novo
assembly methods that don’t require a template?
‘allows to overcome’ − > overcomes
5. p. 3 allows to measure − > measures. Can also
mention other advantages: splice variants, sequence
polymorphisms, no need to design and build a
custom chip
6. ‘correspond to: self suﬃciency’ − > no colon
between preposition and noun phrase. Can the
hallmarks be parallel, all start with noun or verb?
7. p. 9 Eq. 4. How is alpha calculated?
8. Eq. 5 need i = 1 underneath the summation
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9. p. 14. Eq. 16 Under the null, it seems that t,2 should
approach 1/
√
(p) rather than 0.
10. Eq. 16 How is the signiﬁcance of SAM-GS calculated?
11. p. 18 Eq. 24 and text after, use log in math mode
rather than log.
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All comments have been addressed and we revised the
main text correspondingly.
Thank you for your suggestions and comments.
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